Çѱ¹È£½ºÇǽº¡¤¿ÏÈÀÇ·áÇÐȸ 2023³â Á¤±âÃÑȸ ¹× µ¿°èÇмú´ëȸ : 2024-01-20
±³À°ÀÏÀÚ : 2024-01-20
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ
±³À°ÁÖÁ¦ : Çѱ¹È£½ºÇǽº¡¤¿ÏÈÀÇ·áÇÐȸ 2023³â Á¤±âÃÑȸ ¹× µ¿°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹È£½ºÇǽº¤ý¿ÏÈÀÇ·áÇÐȸ
´ã´çÀÚ : ¹Ú¹ÌÁø
¿¬¶ôó : 02-794-8675
À̸ÞÀÏ : hospice@hospicecare.co.kr
±³À°Á¾·ù : ³»°ú, °¡Á¤ÀÇÇаú, ±âŸ
Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í ÀÇ»ç - Á¤È¸¿ø »çÀüµî·Ï: 50,000¿ø, ºñȸ¿ø »çÀüµî·Ï: 90,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 10:20~10:50 ¾Ï¼ºÅëÁõ°ü¸®Áöħ 7ÆÇ °³Á¤ ³»¿ë ¹Ú¼ÒÁ¤(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 10:50~11:20 ¸¶¾à¼º ÁøÅëÁ¦ °ü¸® - ½ÇÅÂ¿Í ³íÀÇ ³ë»ó¹Ì(ÀüÁø»óÀÇ¿ø)
Åä·Ð 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 11:20~11:30 Q&A ()
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 11:40~12:40 Practice of opioid use and continuous IV morphine infusion for pain control ¹ÚÀºÁÖ(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 13:50~14:10 È£½ºÇǽº¡¤¿ÏÈÀÇ·á È«º¸È°µ¿ÀÇ ¾îÁ¦¿Í ¿À´Ã ÃÖÁø¿µ(Áß¾ÓÈ£½ºÇǽº¼¾ÅÍ)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 14:10~14:30 ¾ð·Ð¿¡¼ ´Ù·ïÁö´Â È£½ºÇǽº¡¤¿ÏÈÀÇ·á À̵¿Èñ(MBC)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 14:30~14:50 ȯÀÚ¿Í °¡Á·ÀÌ °æÇèÇϴ ȣ½ºÇǽº¡¤¿ÏÈÀÇ·á ¹éÁø¿µ((»ç)Çѱ¹½ÅÀå¾Ïȯ¿ìȸ)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 14:50~15:10 È£½ºÇǽº¡¤¿ÏÈÀÇ·á ¼³¸íÇϱâ; ÀÇ·áÀι®ÇÐ °üÁ¡¿¡¼ ÀÌÀº¿µ(°æÈñ´ëÇб³ )
Åä·Ð 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 15:10~16:00 Åä·Ð ¹× ÁúÀÇÀÀ´ä À¯»óÈ£,½ÅÇö¿µ,À¯º¸¿µ(´ëÇÑÀÇ·áÄ¿¹Â´ÏÄÉÀ̼ÇÇÐȸ, ±¹È¸º¸°Çº¹ÁöÀ§¿øȸ, º¸°Çº¹ÁöºÎ)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 16:10~16:30 [´ë¸¸] Pain management in the community setting Jen-Kuei Peng(National Taiwan University Hospital)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 16:30~16:50 [ÀϺ»] Treatment of intractable cancer pain in Japan: 10 years after the launch of methadone Eriko Satomi(National Cancer Center Hospital Japan)
±³À°½Ã°£ 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 16:50~17:10 [Çѱ¹] Interventional treatment ¹ÚÁظð(Ä¥°î°æºÏ´ëº´¿ø)
Åä·Ð 01¿ù 20ÀÏ °¡Å縯´ë ¼ºÀDZ³Á¤ ¸¶¸®¾ÆȦ 17:10~17:20 Q&A ()